US equities
|
NVDA
$241.51
▲+1.09%
SPCX
$174.15
▲+1.79%
MU
$1,066.02
▲+0.19%
AMD
$656.80
▲+3.97%
MRVL
$291.87
▲+7.60%
SNDK
$1,670.86
▼-1.95%
AVGO
$378.65
▲+4.45%
TSLA
$380.93
▲+0.58%
NVDA
$241.51
▲+1.09%
SPCX
$174.15
▲+1.79%
MU
$1,066.02
▲+0.19%
AMD
$656.80
▲+3.97%
MRVL
$291.87
▲+7.60%
SNDK
$1,670.86
▼-1.95%
AVGO
$378.65
▲+4.45%
TSLA
$380.93
▲+0.58%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by BELLUS Health Inc.
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
June 16, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
May 16, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
GSK
TSX:BLU
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
May 12, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Announces Meeting Updates
April 26, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
April 18, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
GSK
TSX:BLU
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation
April 05, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
March 21, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Present on the Patient Experience and the Burden of Refractory Chronic Cough at the American Academy of Allergy, Asthma & Immunology Annual Meeting
February 08, 2023
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
November 14, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
November 10, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
October 10, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
September 06, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
August 22, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
August 10, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
July 18, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
July 13, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
July 13, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough
July 12, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Participate in the William Blair Biotech Focus Conference
July 05, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Participate in the Jefferies Healthcare Conference
June 01, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
May 11, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
May 02, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
April 25, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
February 23, 2022
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
December 17, 2021
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
December 14, 2021
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
December 13, 2021
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
December 13, 2021
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
November 10, 2021
From
BELLUS Health Inc.
Via
Business Wire
Tickers
BLU
TSX:BLU
